News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avera Pharmaceuticals, Inc. Completes Enrollment In Phase 2 Social Anxiety Disorder Study


9/25/2006 9:58:31 AM

SAN DIEGO--(BUSINESS WIRE)--Avera Pharmaceuticals, Inc. announced today it has completed enrollment in its ongoing Phase 2 study of the Neurokinin-1 (NK-1) antagonist AV608 in subjects with social anxiety disorder (also called social phobia).

Read at BioSpace.com


comments powered by Disqus
   
Anxiety

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES